Is being a Medical Science Liaison
at risk from AI?
MSLs remain highly resilient due to trust-based relationships, regulatory complexity, and nuanced scientific translation that AI cannot replicate.
Over the next 3-5 years, AI will handle literature synthesis and data queries, but the core MSL function—building credibility with KOLs, navigating institutional politics, and translating complex science in high-stakes clinical contexts—will remain fundamentally human.
What AI can (and can't) do in this role today
Task-by-task assessment, calibrated to current AI capability.
LLMs excel at summarizing clinical trials and meta-analyses, but struggle with nuanced interpretation of conflicting data and clinical relevance.
AI can draft responses to straightforward queries, but regulatory compliance, off-label nuance, and liability concerns require human oversight.
AI can generate slides, but in-person credibility, reading the room, and adapting to skeptical questions remain deeply human skills.
AI can surface publication records and network graphs, but building trust and assessing influence require face-to-face judgment.
AI assists with protocol review and feasibility analysis, but navigating IRBs, institutional priorities, and researcher motivations is human work.
AI can create training materials, but translating field insights into commercial strategy requires contextual understanding and organizational savvy.
What humans still do better
- Trust and credibility with physicians, who scrutinize industry representatives and value peer-level scientific dialogue
- Regulatory and legal guardrails that require human accountability for promotional vs. non-promotional communication
- Ability to read social cues, navigate institutional politics, and adapt messaging in real-time during high-stakes conversations
- Physical presence at medical conferences, hospital rounds, and advisory boards where relationship-building happens
- Deep therapeutic area expertise combined with commercial awareness—a synthesis AI cannot yet replicate authentically
How to raise your resilience as a Medical Science Liaison
Becoming the go-to expert in a complex or emerging therapeutic area (e.g., gene therapy, rare diseases) makes you indispensable when AI-generated summaries lack clinical context or credibility.
Document your network and influence with key opinion leaders; these relationships are your moat and cannot be automated or transferred to AI tools.
Position yourself as the bridge between clinical science and commercial teams—translating field insights into product strategy, medical affairs planning, or market access decisions.
As AI drafts more content, the human who ensures it meets FDA, EMA, and promotional guidelines becomes more valuable, not less.
Orchestrating high-value engagements with thought leaders requires judgment, negotiation, and relationship capital that AI cannot provide.
Frequently asked
Will AI replace Medical Science Liaisons?
No, not in the foreseeable future. The MSL role is built on trust, credibility, and nuanced scientific dialogue with physicians and researchers—capabilities AI cannot replicate. While AI will automate literature reviews and draft responses to information requests, the core function of building relationships with key opinion leaders, navigating institutional politics, and translating complex science in high-stakes clinical contexts remains fundamentally human. Regulatory requirements also mandate human accountability for medical communications, creating a structural barrier to full automation.
What timeline should MSLs worry about for AI disruption?
Over the next 3-5 years, expect AI to become a productivity tool—handling routine literature synthesis, generating draft slide decks, and flagging emerging clinical data. However, the relationship-driven, trust-based aspects of the role will remain intact. The MSLs most at risk are those who treat the job as purely informational (answering queries, distributing reprints) rather than strategic (shaping clinical opinion, advising on research priorities). If you focus on the latter, your timeline for disruption extends well beyond a decade.
What skills should MSLs develop to stay ahead of AI?
Double down on what AI cannot do: building deep therapeutic area expertise, cultivating a network of influential KOLs, and mastering the regulatory and compliance nuances that govern medical affairs. Develop cross-functional leadership skills—translate field insights into commercial strategy, lead advisory boards, and mentor junior MSLs. Learn to use AI tools for efficiency (literature reviews, data queries) so you can spend more time on high-value relationship work. Finally, document your impact: track how your KOL engagement influences clinical practice, publication strategy, or market access decisions.
Will AI impact MSL salaries or job availability?
In the short term, no significant impact. Demand for MSLs remains strong, driven by pharmaceutical innovation (gene therapies, biologics, rare diseases) and the need for credible scientific engagement. Over time, AI may reduce the need for entry-level MSLs who focus on routine information dissemination, but experienced MSLs with strong KOL networks and therapeutic expertise will remain in high demand. Salaries may polarize: top-tier MSLs with strategic influence will command premium compensation, while those in purely transactional roles may see stagnation.
Is it harder for junior MSLs to break in as AI advances?
Potentially, yes. As AI handles more routine tasks (literature summaries, slide generation), entry-level MSL roles may shrink or require higher baseline expertise. New MSLs will need to demonstrate not just scientific knowledge, but also relationship-building skills, commercial acumen, and regulatory fluency from day one. The traditional pathway—PhD or PharmD plus a few years in clinical research—may need to include earlier exposure to KOL engagement, medical communications, or cross-functional pharma teams. However, therapeutic areas with high complexity (oncology, neurology, rare diseases) will continue to hire junior MSLs who can grow into strategic roles.
Does geographic location affect MSL resilience to AI?
Somewhat. MSLs in major biotech hubs (Boston, San Francisco, Research Triangle) or near academic medical centers have more opportunities for high-value KOL engagement and cross-functional collaboration, making them more resilient. Remote MSL roles, which became common post-pandemic, may face more pressure if companies decide AI can handle virtual information requests. However, the need for in-person presence at conferences, advisory boards, and hospital rounds remains strong, giving field-based MSLs a structural advantage over purely remote roles.
What's the biggest mistake MSLs make when thinking about AI?
Treating AI as a threat rather than a tool. The MSLs who thrive will use AI to offload low-value work—literature reviews, data queries, slide drafts—and reinvest that time into relationship-building, strategic advising, and cross-functional leadership. The mistake is clinging to tasks that AI can do well (information retrieval) instead of leaning into what makes you irreplaceable: trust, credibility, and the ability to navigate complex human dynamics in high-stakes clinical and commercial contexts.
Related roles
Want your personal score?
Free, two minutes, no signup. Personalized to your exact tasks, industry, and experience.